Video

leva Pelvic Health System shows efficacy for improving symptoms of urinary incontinence

Author(s):

Urology Times staff

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

In this video, Samantha Pulliam, MD, discusses the background and key findings for the Obstetrics & Gynecology study, “Digital therapeutic device for urinary incontinence: a randomized controlled trial.” Pulliam is chief medical officer for Renovia Inc.

Related Videos
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Timothy Lyon, MD, answers a question during a video interview
Related Content
ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures
January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke
Functional success was achieved in 58% of patients at 5-year follow-up.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
December 17th 2024

Sexual QOL improved at 12 months following AUS placement

LeRoy Jones, MD
"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
© 2025 MJH Life Sciences

All rights reserved.